Stoke Therapeutics Inc (NAS:STOK)
$ 13.05 -0.05 (-0.38%) Market Cap: 690.88 Mil Enterprise Value: 409.98 Mil PE Ratio: 0 PB Ratio: 2.81 GF Score: 40/100

Stoke Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 09:00PM GMT
Esther Rajavelu
UBS - Analyst

Good afternoon, everyone. Thank you for joining us at the UBS Virtual Healthcare Conference day one. I'm excited to have the Stoke Therapeutics management team here with us for a fireside chat. And I'm joined by Ed Kaye, CEO of Stoke. Ed, welcome, and thank you for making time for us today.

Ed Kaye
Stoke Therapeutics, Inc. - CEO & Director

Well, thank you. It's a pleasure to be here, and I look forward to talking about some of our programs.

Esther Rajavelu
UBS - Analyst

Great. So perhaps we can start off with a big picture question here as Stoke is positioned to initiate several trials in the US and EU for the lead program, and you also identified another target from the TANGO platform. So what is the vision here as you continue to make clinical progress across the platform and add to the pipeline?

Ed Kaye
Stoke Therapeutics, Inc. - CEO & Director

So, yes, our expectation and what we're building out is really a full-service

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot